natgillin/translations-raw huggingface dataset:
It is used in pigs to reduce the symptoms of lameness and inflammation in non-infectious locomotor disorders (diseases that affect the ability to move) and for the treatment of diseases that occur after farrowing (giving birth) such as puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome), together with appropriate antibiotic therapy. 
Pri prašičih se uporablja za lajšanje simptomov ohromelosti in vnetja pri neinfekcijskih lokomotornih motnjah (bolezni, ki vplivajo na sposobnost gibanja) ter za zdravljenje bolezni, ki se pojavljajo po kotitvi, kot sta puerperalna septikemija in toksemija (sindrom mastitisa, metritisa in agalakcije),
Emdocam is ‘bioequivalent' to the reference medicine which means that it is equivalent to Metacam in the way it is absorbed and used by the body. 
Zdravilo Emdocam je biološko enakovredno referenčnemu zdravilu, kar pomeni, da je zdravilu Metacam enakovredno glede tega, kako ga telo absorbira in uporablja.
Emdocam is used in horses to relieve colic (abdominal pain) and the inflammation and pain in musculo-skeletal disorders. 
Emdocam se uporablja pri konjih za lajšanje kolike (trebušnih bolečin) ter vnetja in bolečin pri mišičnoskeletnih boleznih.
As the prostaglandins trigger inflammation, pain, exudation and fever, meloxicam reduces these clinical signs. 
Prostaglandini sprožijo vnetje, bolečino, izločanje tekočine in povišano telesno temperaturo, meloksikam pa te klinične znake zmanjšuje.
The CVMP considered that, in accordance with European Union requirements, Emdocam is bioequivalent to Metacam. 
CVMP je menil, da je zdravilo Emdocam v skladu z zahtevami Evropske unije biološko enakovredno zdravilu Metacam.
It is given as a single injection of 0.4 mg per kg body weight into a muscle. 
Daje se kot ena injekcija 0,4 mg na kg telesne mase v mišico.
Emdocam is given in cattle as a single injection of 0.5 mg per kg body weight under the skin or into a vein. 
Zdravilo Emdocam se govedu daje kot ena injekcija 0,5 mg na kg telesne mase pod kožo ali v veno.
Therefore the CVMP's view was that, as for Metacam, Emdocam's benefits are greater than its risks when used for the approved indications. 
CVMP je menil, da so koristi zdravila Emdocam, tako kot pri zdravilu Metacam, večje od z njim povezanih tveganj, če se uporablja za odobrene indikacije.
Consequently, Emdocam's benefit is taken as being the same as that of the reference medicine. 
Zato se šteje, da so koristi zdravila Emdocam enake kot pri referenčnemu zdravilu.
Why has Emdocam been approved? 
Zakaj je bilo zdravilo Emdocam odobreno?
The medicine should not be used in horses producing milk for human consumption. 
Uporaba pri konjih, katerih mleko je namenjeno prehrani ljudi, ni dovoljena
Emdocam was considered to be bioequivalent with the reference medicine. 
Zdravilo Emdocam se je štelo za biološko enakovredno referenčnemu zdravilu.
How has Emdocam been studied? 
Kako je bilo zdravilo Emdocam raziskano?
What is Emdocam used for? 
Za kaj se zdravilo Emdocam uporablja?
How does Emdocam work? 
Kako zdravilo Emdocam deluje?
Emdocam is given as a single injection of 0.6 mg per kg body weight into the horse's vein. 
Daje se kot ena injekcija 0,6 mg na kg telesne mase v konjevo veno.
What is Emdocam? 
Kaj je zdravilo Emdocam?
It is available as tablets (2.5, 5, 7.5, 10 and 15 mg). 
Na voljo je v obliki tablet (2,5 mg, 5 mg, 7,5 mg, 10 mg in 15 mg).
It is known as an ‘atypical' antipsychotic because it is different from the older antipsychotic medicines that have been available since the 1950s. 
Spada med netipična antipsihotična zdravila, ker se razlikuje od starejših antipsihotkov, ki so na voljo od petdesetih let prejšnjega stoletja.
The full EPAR for Olanzapine Cipla can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Olanzapine Cipla je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Previously known as Olanzapine Neopharma. 
Prej znano kot Olanzapine Neopharma.
Its exact mechanism of action is unknown, but it attaches to several receptors on the surface of nerve cells in the brain. 
Natančen mehanizem delovanja zdravila ni znan, vendar pa se zdravilo veže na več receptorjev na površini živčnih celic v možganih.
Schizophrenia is a mental illness that has a number of symptoms including disorganised thinking and speech, hallucinations (hearing or seeing things that are not there), suspiciousness and delusions (mistaken beliefs). 
To je duševna bolezen s številnimi simptomi, ki vključujejo neorganizirano mišljenje in govor, halucinacije (bolnik vidi in sliši stvari, ki jih ni), sumničavost in blodnje (zmotna prepričanja).
It can also be used to prevent the recurrence of these episodes (when symptoms come back) in adults with bipolar disorder (a mental illness causing alternating periods of high mood and depression) who have responded to an initial course of treatment. 
Uporablja se lahko tudi za preprečevanje ponovnega pojava simptomov teh epizod pri odraslih z bipolarno motnjo (duševno boleznijo, pri kateri se izmenjujejo obdobja privzdignjenega razpoloženja in depresije), ki so se odzvali na začetno zdravljenje.
The recommended starting dose of Olanzapine Cipla depends on the disease being treated: 10 mg per day is used in schizophrenia and in the prevention of manic episodes, and 15 mg per day in the treatment of manic episodes, unless it is used with other medicines, in which case the starting dose can be 10 mg per day. 
Priporočeni začetni odmerek zdravila Olanzapine Cipla je odvisen od bolezni, ki jo zdravimo: pri shizofreniji in za preprečevanje maničnih epizod se uporablja 10-miligramski odmerek na dan, pri zdravljenju maničnih epizod pa se uporablja 15-miligramski odmerek na dan, razen ob souporabi drugih zdravil, ko lahko začetni odmerek znaša 10 mg na dan.
It is thought that olanzapine's beneficial effect is due to it blocking receptors for the neurotransmitters 5-hydroxytryptamine (also called serotonin) and dopamine. 
Domneva se, da so koristni učinki olanzapina posledica zaviranja receptorjev za živčna prenašalca 5-hidroksitriptamin (imenovan tudi serotonin) in dopamin.
The European Commission granted a marketing authorisation valid throughout the EU for Olanzapine Neopharma on 14 November 2007. 
Evropska komisija je dovoljenje za promet z zdravilom Olanzapine Neopharma, veljavno po vsej Evropski uniji, odobrila dne 14. novembra 2007.
The dose is adjusted depending on how well the patient responds to and tolerates the treatment. 
Zdravnik odmerek prilagodi glede na to, kako se bolnik odziva na zdravljenje in kako zdravljenje prenaša.
Olanzapine Cipla is a ‘generic medicine'. 
Olanzapine Cipla je „generično zdravilo“.
Since these neurotransmitters are involved in schizophrenia and bipolar disorder, olanzapine helps to normalise the activity of the brain, reducing the symptoms of these diseases. 
Ker ta dva živčna prenašalca običajno sodelujeta pri shizofreniji in bipolarni motnji, olanzapin pomaga normalizirati delovanje možganov in tako zmanjša simptome teh bolezni.
Patients over 65 years of age and patients who have problems with their liver or kidneys may need a lower starting dose of 5 mg per day. 
Običajni razpon odmerkov je od 5 do 20 mg na dan. Bolniki, starejši od 65 let, in bolniki, ki imajo težave z jetri ali ledvicami, bodo morda potrebovali nižji začetni odmerek, in sicer 5 mg na dan.
For more information about treatment with Olanzapine Cipla, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Olanzapine Cipla preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
This disrupts signals transmitted between brain cells by ‘neurotransmitters', chemicals that allow nerve cells to communicate with each other. 
S tem se prekine prenos signalov med možganskimi celicami prek živčnih prenašalcev, tj. kemičnih snovi, ki omogočajo medsebojno komunikacijo med živčnimi celicami.
Olanzapine Cipla is also effective in maintaining improvement in patients who have responded to an initial course of treatment. 
Zdravilo Olanzapine Cipla je prav tako učinkovito pri vzdrževanju izboljšanja stanja pri bolnikih, ki so se odzvali na začetno zdravljenje.
The name of the medicine was changed to Olanzapine Cipla on 16 May 2013. 
Ime zdravila je bilo 16. maja 2013 spremenjeno v Olanzapine Cipla.
This means that Olanzapine Cipla is similar to a ‘reference medicine' already authorised in the European Union (EU) called Zyprexa. 
To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Zyprexa.
What are the benefits and risks of Olanzapine Cipla? 
Kakšne so koristi in tveganja, povezani z zdravilom Olanzapine Cipla?
This is a summary of the European public assessment report (EPAR) for Olanzapine Cipla. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Olanzapine Cipla.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Olanzapine Cipla. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Olanzapine Cipla, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
The CHMP concluded that, in accordance with EU requirements, Olanzapine Cipla has been shown to have comparable quality and to be bioequivalent to Zyprexa. 
CHMP je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Olanzapine Cipla primerljivo raven kakovosti kot zdravilo Zyprexa ter da mu je biološko enakovredno.
Olanzapine Cipla is also used to treat moderate to severe manic episodes (extremely high mood) in adults. 
Zdravilo Olanzapine Cipla se uporablja tudi za zdravljenje zmernih do hudih maničnih epizod (izjemno privzdignjenega razpoloženja) pri odraslih.
Because Olanzapine Cipla is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as the reference medicine's. 
Ker je zdravilo Olanzapine Cipla generično zdravilo in je biološko enakovredno referenčnemu zdravilu, so koristi in tveganja enaki kot pri referenčnem zdravilu.
Olanzapine Cipla 1 
Olanzapine Cipla olanzapin
Because Olanzapine Cipla is a generic medicine, studies in patients have been limited to tests to demonstrate that it is bioequivalent to the reference medicine, Zyprexa. 
Ker je zdravilo Olanzapine Cipla generično zdravilo, so bile študije omejene na preskuse za ugotavljanje, ali je biološko enakovredno referenčnemu zdravilu Zyprexa.
Therefore, the CHMP's view was that, as for Zyprexa, the benefit outweighs the identified risk. 
Zato je menil, da koristi, tako kot pri zdravilu Zyprexa, odtehtajo znana tveganja.
Olanzapine Cipla is a medicine that contains the active substance olanzapine. 
Olanzapine Cipla je zdravilo, ki vsebuje zdravilno učinkovino olanzapin.
Why has Olanzapine Cipla been approved? 
Zakaj je bilo zdravilo Olanzapine Cipla odobreno?
Olanzapine Cipla is used to treat adults with schizophrenia. 
Zdravilo Olanzapine Cipla se uporablja za zdravljenje shizofrenije.
The active substance in Olanzapine Cipla, olanzapine, is an antipsychotic medicine. 
Zdravilna učinkovina zdravila Olanzapine Cipla je olanzapin, ki je antipsihotično zdravilo.
Other information about Olanzapine Cipla 
Druge informacije o zdravilu Olanzapine Cipla
The Committee recommended that Olanzapine Cipla be given marketing authorisation. 
Priporočil je, da se za zdravilo Olanzapine Cipla odobri dovoljenje za promet.
What is Olanzapine Cipla used for? 
Za kaj se zdravilo Olanzapine Cipla uporablja?
What is Olanzapine Cipla? 
Kaj je zdravilo Olanzapine Cipla?
How has Olanzapine Cipla been studied? 
Kako je bilo zdravilo Olanzapine Cipla raziskano?
How is Olanzapine Cipla used? 
Kako se zdravilo Olanzapine Cipla uporablja?
How does Olanzapine Cipla work? 
Kako zdravilo Olanzapine Cipla deluje?
Among these, dyskinesia (difficulty controlling movement) may affect around 2 in 10 people. 
Od teh lahko diskinezija (težave z nadzorovanjem gibanja) prizadene približno 2 osebi od 10.
What measures are being taken to ensure the safe and effective use of Ongentys? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Ongentys?
Ongentys must not be used in: 
Zdravilo Ongentys se ne sme uporabljati pri:
The full EPAR for Ongentys can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Ongentys je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Ongentys's benefits are greater than its risks and recommended that it be approved for use in the EU. 
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Ongentys večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
Fluctuations happen when the effects of the medication wear off and symptoms re-emerge before the next dose is due. 
Nihanja se pojavijo, ko učinki zdravila pojenjajo in se simptomi ponovno pojavijo še pred naslednjim odmerkom.
This is a summary of the European public assessment report (EPAR) for Ongentys. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Ongentys.
It is not intended to provide practical advice on how to use Ongentys. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Ongentys have been included in the summary of product characteristics and the package leaflet. 
Priporočila in previdnostni ukrepi, ki jih morajo zdravstveni delavci in bolniki upoštevati za varno in učinkovito uporabo zdravila Ongentys, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
In both studies, patients had on average off periods of about 6 to 7 hours at the start of the study. 
V obeh študijah je čas izklopa pri bolnikih ob začetku študije povprečno znašal od 6 do 7 ur.
The benefits of Ongentys in Parkinson's disease were investigated in two main studies. 
Koristi zdravila Ongentys pri Parkinsonovi bolezni so proučevali v dveh glavnih študijah.
Regarding its safety, Ongentys was considered to be comparable to other medicines of the same class. 
Z vidika varnosti je bilo zdravilo Ongentys ocenjeno kot primerljivo z drugimi zdravili istega razreda.
Both studies were extended for one additional year and confirmed the benefits of Ongentys when used long-term. 
Obe študiji so podaljšali za eno leto, s čimer so potrdili koristi dolgotrajne uporabe zdravila Ongentys.
Opicapone blocks an enzyme that is involved in the breakdown of levodopa in the body called catechol-O-methyl transferase (COMT). 
Opikapon blokira encim, ki sodeluje pri razgradnji levodope v telesu, imenovan katehol-O-metiltransferaza (COMT).
This study looked at how well the treatments reduced the time when patients have more difficulty moving about, called ‘off periods'. 
V tej študiji so proučevali, kako učinkovito so zdravila skrajšala čas, ko so imeli bolniki več težav z gibanjem - „čas izklopa“.
Ongentys is available as capsules (25 mg and 50 mg) to be taken by mouth. 
Zdravilo Ongentys je na voljo v obliki kapsul (25 mg in 50 mg), ki se jemljejo peroralno.
Ongentys is used when these fluctuations cannot be treated with the standard levodopa-containing combinations alone. 
Zdravilo Ongentys se uporablja, kadar teh nihanj ni možno zdraviti samo s standardnimi kombinacijami, ki vsebujejo levodopo.
Other information about Ongentys 
Druge informacije o zdravilu Ongentys
They are linked to a reduction in the effect of levodopa, when the patient experiences sudden switches between being ‘on' and able to move, and being ‘off' and having difficulty moving about. 
Povezana so z zmanjšanim učinkom levodope, ko bolnik doživlja nenadne preskoke med stanjem„vklopa“, ko se lahko giba, in stanjem „izklopa“, ko ima težave z gibanjem.
The patients then lose their ability to control their movements reliably. 
Bolniki nato izgubijo zmožnost zanesljivega nadzorovanja gibov.
The recommended dose is 50 mg, taken once a day at bedtime, at least one hour before or after levodopa combination medicines. 
Priporočeni odmerek je 50 mg enkrat na dan pred spanjem vsaj eno uro pred zdravilom s kombinacijo levodope ali po njem.
• patients taking medicines known as non-selective monoamine oxidase (MAO) inhibitors except when used to treat Parkinson's disease. 
• bolnikih, ki prejemajo zdravila, znana kot neselektivni zaviralci monoaminoksidaze (MAO), razen pri uporabi za zdravljenje Parkinsonove bolezni.
For more information about treatment with Ongentys, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Ongentys preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
What is Ongentys and what is it used for? 
Kaj je zdravilo Ongentys in za kaj se uporablja?
For practical information about using Ongentys, patients should read the package leaflet or contact their doctor or pharmacist. 
Za praktične informacije o uporabi zdravila Ongentys naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
What are the risks associated with Ongentys? 
Kakšna tveganja so povezana z zdravilom Ongentys?
It enhances the effects of levodopa, a copy of the neurotransmitter dopamine that can be taken by mouth. 
Okrepi učinke levodope, kopije živčnega prenašalca dopamina, ki se lahko jemlje peroralno.
• patients with a history of neuroleptic malignant syndrome (a nervous system disorder usually caused by antipsychotic medicines) or rhabdomyolysis (breakdown of muscle fibres); 
• bolnikih z anamnezo nevroleptičnega malignega sindroma (bolezni živčevja, ki jo običajno povzročijo antipsihotiki) ali rabdomiolize (razgradnje mišičnih vlaken);
Why is Ongentys approved? 
Zakaj je bilo zdravilo Ongentys odobreno?
What benefits of Ongentys have been shown in studies? 
Kakšne koristi je zdravilo Ongentys izkazalo v študijah?
Ongentys is a medicine used to treat adults with Parkinson's disease, a progressive brain disorder that causes shaking and muscle stiffness, and slows movement. 
Zdravilo Ongentys se uporablja za zdravljenje odraslih s Parkinsonovo boleznijo, tj. napredujočo okvaro možganov, ki povzroča tresenje in togost mišic ter upočasnjeno gibanje.
In the second study, which also looked at the reduction in off periods, Ongentys was compared with placebo in 427 patients who were taking a levodopa / DDCI combination. 
V drugi študiji, v kateri so prav tako proučevali skrajšanje časa izklopa, so pri 427 bolnikih, ki so prejemali kombinacijo z levodopo/zaviralci DDK, zdravilo Ongentys primerjali s placebom.
The active substance in Ongentys, opicapone, works to restore the levels of dopamine in the parts of the brain that control movement and coordination. 
Zdravilna učinkovina v zdravilu Ongentys, opikapon, deluje tako, da obnovi ravni dopamina v predelih možganov, ki nadzorujejo gibanje in koordinacijo gibov.
• patients with tumours of the adrenal glands (small glands located on top of the kidneys) such as pheochromocytoma and paraganglioma; 
• bolnikih s tumorjem nadledvičnih žlez (majhnih žlez na vrhu ledvic), kot sta feokromocitom in paragangliom;
For the full list of all side effects reported with Ongentys, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Ongentys, glejte navodilo za uporabo.
The most common side effects with Ongentys are disorders of the nervous system (brain and spinal cord). 
Najpogostejši neželeni učinki zdravila Ongentys so bolezni živčevja (možganov in hrbtenjače).
Ongentys contains the active substance opicapone. 
Zdravilo Ongentys vsebuje zdravilno učinkovino opikapon.
After 14-15 weeks, off periods were shortened by 117 minutes (almost 2 hours) in patients taking Ongentys 50 mg, compared with 96 minutes (about 1 and a half hour) in patients taking the comparator medicine entacapone and 56 minutes (less than 1 hour) in patients taking placebo. 
Po preteku 14 do 15 tednov se je čas izklopa pri bolnikih, ki so prejemali zdravilo Ongentys 50 mg, skrajšal za 117 minut (skoraj dve uri), pri bolnikih, ki so prejemali primerjalno zdravilo entakapon, za 96 minut (okrog eno uro in pol), pri bolnikih, ki so prejemali placebo, pa za 56 minut (manj kot eno uro).
Ongentys is used as an add-on to levodopa / DOPA decarboxylase inhibitors (DDCI) (other medicines for Parkinson's disease) in patients who are having fluctuations in the control of their condition. 
Zdravilo Ongentys se uporablja kot dodatno zdravljenje k zdravilom z levodopo/zaviralci dopa dekarboksilaze (DDK) (drugim zdravilom proti Parkinsonovi bolezni) pri bolnikih z nihanji pri nadzoru bolezni.
After 14-15 weeks, off periods were shortened by 119 minutes (almost 2 hours) in patients taking Ongentys 50 mg, compared with 64 minutes in patients taking placebo. 
Po preteku 14 do 15 tednov se je čas izklopa pri bolnikih, ki so prejemali zdravilo Ongentys 50 mg, skrajšal za 119 minut (skoraj dve uri), pri bolnikih, ki so prejemali placebo, pa za 64 minut.
In the first study, 600 patients with fluctuations were given Ongentys, entacapone (another medicine for Parkinson's disease) or placebo (a dummy treatment), in addition to their current levodopa / DDCI combination. 
V prvi študiji je 600 bolnikov z nihanji poleg kombinacije z levodopo/zaviralci DDK, ki so jo že prejemali, prejemalo zdravilo Ongentys, entakapon (drugo zdravilo proti Parkinsonovi bolezni) ali placebo (zdravilo brez zdravilne učinkovine).
How is Ongentys used? 
Kako se zdravilo Ongentys uporablja?
Ongentys was shown to be more effective than placebo and at least as effective as the comparator entacapone in reducing off periods in patients with Parkinson's disease taking levodopa combination medicines. 
Zdravilo Ongentys se je pri skrajševanju časa izklopa pri bolnikih s Parkinsonovo boleznijo, ki so jemali zdravila z levodopo, pokazalo kot učinkovitejše od placeba in vsaj tako učinkovito kot primerjalno zdravilo entakapon.
How does Ongentys work? 
Kako zdravilo Ongentys deluje?
This helps to improve the symptoms of Parkinson's disease, such as stiffness and slowness of movement. 
Tako ostane levodopa aktivna dlje, kar pomaga izboljšati simptome Parkinsonove bolezni, kot je togost in upočasnjeno gibanje.
036 80 Martin Slovak Republic 
036 80 Martin Slovaška republika
The recommended dose is 
Priporočeni odmerek je
The safety and efficacy of sildenafil was maintained in long-term studies. 
Varnost in učinkovitost sildenafila sta se ohranili tudi v dolgoročnih študijah.
It is not possible to determine whether these events are related directly to these factors or to other factors. 
Ali so ti dogodki neposredno povezani s temi dejavniki ali pa z drugimi dejavniki, ni mogoče ugotoviti.
There are no adequate and well-controlled studies in pregnant or breast-feeding women. 
Ni zadostnih in dobro nadzorovanih študij pri nosečnicah in doječih ženskah.
Please tell your doctor about this. 
O tem obvestite zdravnika.
● Risk Management Plan (RMP) Not applicable. 
• Načrt za obvladovanje tveganja (RMP) Navedba smiselno ni potrebna.
Most, but not all, of these patients had pre-existing cardiovascular risk factors. 
Večina teh bolnikov, ne pa vsi, je imela že prej obstoječe kardiovaskularne dejavnike tveganja.
However, due to high inter-subject variability, these differences were not statistically significant. 
Vendar te razlike zaradi velike variabilnosti med posamezniki niso bile statistično značilne.
Alcoholic drink can make erection difficulties worse. 
Alkoholne pijače lahko poslabšajo težave z erekcijo.